SLC5A2 and hydrops fetalis: According to ESC 2021 guidelines, sodium-glucose co-transporter 2 (SGLT2) inhibitors added to a therapy with ACE-I/ARNI/beta-blocker/MRA reduced the risk of CV death and worsening HF in patients with HFrEF.